Keyphrases
Myelodysplastic Syndrome
93%
Acute Myeloid Leukemia
74%
Myelodysplasia
27%
Chronic Lymphocytic Leukemia
26%
International Working Groups
21%
Glycogen Synthase Kinase 3 (GSK3)
20%
Myelodysplastic
17%
Marrow
15%
Reduced-intensity Conditioning
14%
Dysregulation
13%
Autophagy
13%
Tenovin-6
13%
Revised International Prognostic Scoring System
13%
Myeloproliferative Neoplasms
13%
Elraglusib
13%
Allograft
12%
Protein Expression
12%
Leukemia Patients
10%
Ring Sideroblasts
10%
Disease Relapse
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Clinical Features
9%
Clinical Benefit
9%
Overall Survival
9%
Graft-versus-host Disease (GvHD)
9%
Alemtuzumab
9%
Myeloid Malignancies
9%
P53 Pathway
8%
Potential Contribution
8%
SF3B1 mutation
8%
SF3B1
8%
Stem Cell Transplantation
8%
Small Molecules
8%
Chronic Lymphocytic Leukemia Cells
8%
Cytopenia
8%
Apoptosis
8%
Prognostic Scoring System
8%
Intensive Chemotherapy
8%
Hemoglobin Level
7%
Disease Subtypes
7%
Prognostic Marker
7%
Clinical Practice Guidelines
7%
Prognostic Groups
7%
9-ING-41
7%
Stromal Microenvironment
7%
Hematopoiesis
7%
Sirtuin Inhibitors
7%
Cytotoxicity
7%
Disease Phenotype
7%
World Health Organization Classification
7%
Medicine and Dentistry
Myelodysplastic Syndrome
100%
Acute Myeloid Leukemia
71%
Diseases
38%
Allogeneic Stem Cell Transplantation
16%
Somatics
14%
International Prognostic Scoring System
13%
B-Cell Chronic Lymphocytic Leukemia
13%
Protein P53
13%
Myeloproliferative Neoplasm
13%
Stroma
13%
Reduced Intensity Conditioning
10%
Clinical Feature
9%
Allograft
9%
Health Care Cost
9%
Cytopenia
8%
Scoring System
8%
T Cell
8%
Overall Survival
7%
Myeloid Malignancy
7%
Cancer
7%
Hematopoiesis
7%
Clinical Trial
7%
Protein Expression
6%
Iron Chelating Agent
6%
Disease Free Survival
6%
Chronic Myelogenous Leukemia
6%
Intensive Care
6%
Tyrosine-Kinase Inhibitor
6%
Janus Kinase 2
6%
Cytomegalovirus
6%
Tetramer
6%
Stem Cell Transplant
6%
Adoptive Transfer
6%
Pathophysiology
6%
Prevalence
6%
Cell Cycle
6%
Cancer Stem Cell
6%
Autophagy
6%
Long Term Survival
6%
Socioeconomic Status
6%
Calreticulin
6%
Clinical Significance
6%
Lymphocyte
6%
Iron
6%
In Vitro
6%
Supportive Care
5%
Programmed Cell Death
5%
Cytarabine
5%